For U.S. healthcare professionals only
Smiling man sitting in front of a brightly colored mural he's painted, with multiple scenes showing swimming, hiking, and other activity.
When it comes to their goals, your patients are never done.

When on ADVATE®, your hemophilia A patient can keep building on the foundation you’ve helped them establish with the TAKEDA FVIII family.

Because There's More to Their Stories
Learn More About ADVATE

Indications and Limitations of Use: ADVATE [Antihemophilic Factor (Recombinant)] is a recombinant antihemophilic factor indicated for use in children and adults with hemophilia A for the control and prevention of bleeding episodes. ADVATE is not indicated for the treatment von Willebrand disease.

*In clinical trials, ADVATE has demonstrated the ability to help patients prevent bleeding episodes using a prophylaxis regimen.

ADVATE has a legacy of real-world treatment experience and provides clinically proven bleed protection.*1


What is ADVATE?

ADVATE is a plasma/albumin-free recombinant factor VIII replacement therapy for patients with hemophilia A.1,2

ADVATE is indicated for prophylaxis, on-demand, and perioperative use in children and adults with hemophilia A and has an established safety profile.1,3
Access & Resources

Takeda has a variety of resources to help you and your patient navigate access to ADVATE.


ADVATE dosing can be personalized for your patients based on their factor VIII replacement therapy needs.1

  1. Advate. Prescribing information. Baxalta US Inc; 2018.
  2. Grillberger L, Kreil TR, Nasr S, Reiter M. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J. 2009;4(2):186-201. doi:10.1002/biot.200800241
  3. Shapiro AD, Schoenig-Diesing C, Silvati-Fidell L, Wong WY, Romanov V. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A. Haemophilia. 2015;21(6):791-798. doi:10.1111/hae.12724